Key facts
- This page summarizes David Cordani's Form 4 filing for Cigna Group (CI).
- 21 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 14 May 2026, 16:47.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Options Exercise
Options Exercise
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Footnote F2
Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F4
Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F5
Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F6
Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F7
Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F8
Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F9
Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F10
Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F11
Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F12
Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F13
Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F14
Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Footnote F15
Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
Footnote F16
This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.
Footnote F17
This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.
SEC remarks
Exhibit 24 - Power of Attorney